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 ABSTRACT 
 
Monoclonal gammopathies are a heterogeneous group of disorders characterized by clonal proliferation of 
immunoglobulin produced by B-lymphocytes or plasma cell clone. 
The term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal 
gammopathies that result in the development of kidney disease from those that are benign. 
Screening for monoclonal immunoglobulin and an appropriate hematologic workup are fundamental and 
sometimes a difficult challenge, with therapeutic and prognostic implications. Kidney biopsy is essential to deter-
mine the exact nature of the lesion and to evaluate the severity of renal disease.
In this review we discuss the clinical and pathologic features of MGRS, highlighting the most diagnostic dif-
ficulties and current therapeutic options. 
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 INTRODUCTION
Monoclonal gammopathies are a heterogeneous 
group of disorders characterized by clonal proliferation 
of immunoglobulin produced by B-lymphocytes or 
plasma cell clone. The spectrum includes the benign 
condition known as monoclonal gammopathy of unde-
termined significance (MGUS), low grade lymphoplas-
macytic lymphoma with Waldenstrom’s macroglobu-
linemia (WM), chronic lymphocytic leukemia (CLL), 
B-cell lymphoma and multiple myeloma (MM).
MGUS is defined as a plasma cell proliferative dis-
order with the presence of serum M-protein <3g/dL 
or < 10% bone marrow clonal plasma cells and it is not 
associated with end organ damage1. The term mono-
clonal gammopathy of renal significance (MGRS) was 
introduced to distinguish monoclonal gammopathies 
that result in the development of kidney disease from 
those that are benign2. MGRS do not meet criteria for 
MM, WM, CLL or malignant lymphoma but can be asso-
ciated with high morbidity due to renal lesions induced 
by a monoclonal immunoglobulin (MIg)2. 
An incidentally identification of monoclonal gam-
mopathy should be followed by renal evaluation. On the 
other hand, unexplained proteinuria or renal dysfunction 
should involve monoclonal protein screening.
The importance of differentiating the term MGRS 
from other monoclonal gammopathies lies in the fact 
that diagnostic and therapeutic procedures aimed at 
controlling monoclonal protein synthesis and secre-
tion can be indicated. Because treatment is not rec-
ommended for MGUS, appropriate therapy is com-
monly withheld but, in MGRS clone-directed therapy 
is required for disease control and has impact on the 
outcome.
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In this review we discuss the clinical and pathologic 
features of MGRS, highlighting the most diagnostic dif-
ficulties and current therapeutic options. 
 HEMATOLOGIC EVALUATION
The M protein may consist of a heavy (commonly G, 
less commonly M, and rarely A, E or D chain) and light 
chain (either Kappa(κ) or lambda(λ)), light chain only, or 
less commonly, heavy chain only. The presence of a clonal 
IgM suggests a B cell or mixed B and plasma cell clone. 
M-protein can be traced in the serum and/or urine 
in almost all patients, but diagnostic approach in MGRS 
should be sensitive enough to detect “small” plasma 
cell and B cell clones.
A complete screening with urine electrophoresis, 
immunofixation studies and free light-chain assays (FLC) 
is obligatory even if serum protein electrophoresis 
(SPEP) studies are negative. In some cases, the MIg 
levels are very small and may not be detected by EP 
that is why serum and urine immunofixation is recom-
mended3. FLC assay suggests clonality by comparing 
the concentration and ratio of kappa to lambda in the 
serum, for that matter, it is useful at diagnosis and as 
indicator of response to treatment4. In case of renal 
impairment, low renal clearance of polyclonal FLC 
induces an elevation of FLC kappa (κ) and lambda (λ) 
levels. Considering a reference range of 0.37-3.17 has 
been shown to increase diagnostic accuracy5. 
To characterize the clone, a detailed hematologic 
evaluation should be performed with bone marrow 
aspirate and biopsy with immunohistological studies. 
Flow cytometry can detect clonal populations below 
the limits of immunostaining3,6,7. Computed tomogra-
phy scan should be performed in patients with high 
suspicion for lymphoma or in those with monoclonal 
IgM, in order to identify pathologically involved lymph 
nodes for a diagnostic biopsy3,6. 
  CLINICAL, PATHOLOGY AND 
TREATMENT CONSIDERATIONS
Diagnosis requires integration of clinical parameters, 
serum and urine analysis, and structural alterations 
identified by light microscopy, immunofluorescence (IF) 
and electron microscopy (EM). Anatomopathological 
characteristics are presented in Table 1. In difficult cases, 
immunoEM and mass spectrometry may be required 
to confirm the composition of renal deposits8,9.
The immunoglobulin (Ig) deposits associated to 
MGRS can be classified into two categories: with organ-
ized and with non-organized deposits. MGRS with 
organized deposits includes Ig related amyloidosis, 
fibrillar glomerulonephritis, immunotactoid and type 
I cryoglobulinemic glomerulonephritis. MGRS with non-
organized electro-dense granular deposits includes 
monoclonal immunoglobulin deposition disease, pro-
liferative glomerulonephritis with monoclonal IgG 
deposits and C3 glomerulopathy with monoclonal gam-
mopathy. MGRS also includes tubular disorders such 
as light chain proximal tubulopathy12.
Most of these disorders are characterized by deposi-
tion and precipitation of MIg in the different compo-
nents of the kidney (glomeruli, vessels, interstitium)13. 
MIg can also induce renal injury by dysregulation of the 
complement pathway14, or by acting like autoantibodies 
against complement factor or phospholipase A2 recep-
tor15. Other mechanisms are still to be explained.
Treatment is required when symptoms related to 
the underlying proliferative process are present. No 
strategy is available in daily practice to inhibit MIg 
tissue deposition or to clear the already deposited 
material4. A recent clinical trial with humanized mono-
clonal IgG1 anti-serum amyloid P component antibody 
safely triggered clearance of amyloid deposits from 
the liver and some other tissues16. Cytotoxic therapy 
adapted to the underlying clone and renal function 
has been shown to improve renal outcome and patient 
survival14,17-19. If a detectable circulating paraprotein 
is present, response to treatment can be monitor by 
paraproteins levels (EP, serum and urine immunofixa-
tion, FLC). 
The agents used to treat MGRS have activity against 
B cell and plasma cell disorders. The therapeutic regi-
men chosen should be based on the International Kidney 
and Monoclonal Gammopathy Working Group consen-
sus4. Corticosteroids are usually part of these regimens, 
in monotherapy in cases of mild disease or combined 
in more severe disease. Bortezomib is a proteasome 
inhibitor. It can be given at full doses in renal insuffi-
ciency and has no renal toxicity. Prophylaxis against 
herpes zoster reactivation is mandatory20. Cyclophos-
phamide and melphalan are cytotoxic agents, targeting 
both plasma cell and B cell. Cyclophosphamide is pre-
ferred to melphalan due to its lower toxicity.
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Bendamustine, with features from alkylating agents 
and purine analogs, also has a predominantly nonrenal 
metabolism and can be given to patients with end stage 
renal disease (ESRD). Rituximab is a monoclonal anti-
body directed at CD20, and its use raises no concerns 
in patients with renal impairment, including ESRD.
 RENAL LESIONS ASSOCIATED WITH MGRS
Immunoglobulin related amyloidosis is secondary 
to the deposition of immunoglobulin (Ig) produced by 
clonal plasma cells in tissue as amyloid. 
AL amyloidosis can be diagnosed if AL deposits can 
be demonstrated in other tissues such as fat. Microdis-
section and mass spectrometry can identify the type 
of renal amyloidosis in more than 97% of cases and 
can distinguish it from non-amyloid fibrillar glomeru-
lopathy 21,22. A detailed discussion of this pathology 
goes beyond the scope of this article.
Monoclonal immunoglobulin deposition disease 
(MIDD) is secondary to deposition of light‑chain (κ in 
most cases), light and heavy chain, and heavy chain 
deposition disease13.The deposits lack affinity for Congo 
red and do not have a fibrillar organization23. Most often 
presents in the sixth decade, in the presence of renal 
insufficiency and proteinuria and hypertension24. 
Fibrillary glomerulonephritis (FGN) occurs in 
patients with solid malignancies, autoimmune dis-
eases, and hepatitis C. It is nearly always character-
ized by polyclonal IgG deposits without a detectable 
clonal B-cell disorder; the reason it is not considered 
an MGRS by some groups25,26. Most often presents 
with proteinuria, 50% within nephrotic range, with 
or without renal insufficiency, hematuria or hyperten-
sion25,26. Deposits are thicker than amyloid and are 
Congo red negative26. In a case series report, M-spike 
was detected by SPEP/immunofixation in only 16% 
of 61 patients27. 
Immunotactoid (microtubular) glomerulopathy 
(ITG) occurs in an older population and  typically pre-
sents as a nephrotic syndrome. Cryoglobulinemic GN 
must be ruled out, because they are difficult to dif-
ferentiate histopathologically. ITG is associated with an 
underlying hematologic malignancy such as CLL or small 
lymphocytic lymphoma, but the association with MGRS 
is also possible28. Therapeutic choice depends on the 
underlying disorder. In patients with gammopathy only, 
the role of rituximab is questionable and bortezomib-
based therapy may be considered4. 
Table 1
Pathological characteristics of MGRS. Adapted from Correia SO et al. MGRS: Diagnostic workup10
AL/AH/AHL MIDD FGN ITG PGNMI
Type 1  
cryoglobulinemic 
GN
C3 glomerulopathy 
with MG
LM
Acellular, 
mesangial/lobular 
deposits;  
Congo red positive 
[or Amytracker™ 
545a positive]
Nodular 
glomerulosclerosis, 
Thickened tubular 
basement 
membrane and 
vascular wall
Mesangial 
proIiferation, MPGN 
pattern, Congo red 
negative
Mesangial GN, 
Membranous GP, 
MPGN pattern
MPGN pattern, 
Endocapillary, 
mesangial GN, 
Membranous GP
MPGN pattern, 
Endocapillary GN
MPGN pattern, 
Endocapillary 
proliferative GN, 
Mesangial GN
IF
LC and/or HC 
deposits
lg deposits in 
tubular basement 
membrane and 
vascular wall
lgG polyclonal
lgG often 
monotypic; C3, C4, 
C1q
Monoclonal lgG, 
rarely: lgM or lgA 
(restricted to the 
glumerulus)
Monoclonal lgG or 
lgM; C3,C4,C1q 
deposits
Granular C3 
deposits
EM
Organized,  
random 
nonbranching 
fibrils, 8-10 nm
Non organized, 
punctate dense 
deposits on 
glomerular, vascular 
and tubular 
membrane
Organized, random 
fibrils, 12-24 nm 
(mostly 18-20 nm)
Organized, parallel, 
microtubular (>30 
nm)
Non organized 
deposits in 
mesangium, 
subendothelial and 
intramembranous 
zone
Organized, 
microtubular  
or vague, short 
fibrillary
DDD: 
intramembranous 
deposits; C3GN: 
mesangial, 
subendothelial and/
or subepithelial 
deposits
a New sensitive method for early detection of amyloidosis in humans11; AH: Immunoglobulin heavy chain; AHL: Immunoglobulin heavy and light chain; AL: Immunoglobulin light 
chain; C3GN: C3 glomerulonephritis; DDD: Dense deposits disease; EM: Electronic microscopy; EP: Electrophoresis; FGN: Fibrillary glomerulonephritis; FLC: Free light chain assay; 
GN: Glomerulonephritis; GP: Glomerulopathy; IF: Immunofluorescence; Ig: Immunoglobulin; ITG: Immunotactoid glomerulonephritis; LC: Light chain; LM: Light microscopy; MG: 
Monoclonal gammopathy; MIDD: Monoclonal immunoglobulin deposition disease; MPGN: Membranoproliferative glomerulonephritis; PGNMID: Proliferative glomerulonephritis 
with monoclonal immunoglobulin deposits.
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Proliferative glomerulonephritis with monoclonal 
IgG Deposits (PGNMID)  typically presents with proteinu-
ria, variable degrees of hematuria, renal insufficiency 
and hypertension. The diagnosis is established by 
EM29,30. Some authors are reluctant to recommend 
chemotherapy in PGNMID with no detectable MIg. The 
presence of an underlying B-cell disorder is suggested 
by the presence of monotypic glomerular deposits and 
the recurrence after renal transplantation29,31. The Inter-
national Kidney and Monoclonal Gammopathy Research 
Group recommends chemotherapy (Cyclophosphamide 
and bortezomib) in patients with stages 1 and 2 CKD and 
high-grade proteinuria (>1 g/day) or progressive disease, 
and in patients with stages 3 and 4 CKD4. 
Cryoglobulinemic glomerulonephritis presents 
mainly in a membranoproliferative pattern. Type 1 
cryoglobulinemia is monoclonal, usually composed of 
an IgM but can be IgG or IgA, is associate with plasma 
cell dyscrasias or B-cell lymphoproliferative disorders 
(multiple myeloma, Waldenstrom macroglobulinemia, 
chronic lymphocytic leukemia, B-cell non-Hodgkin lym-
phoma, MGRS, and hairy cell leukemia)32,33. 
Type 2 mixed cryoglobulins are composed of an MIg, 
usually an IgM k with a rheumatoid factor activity, asso-
ciated with polyclonal immunoglobulin. The most com-
mon cause is hepatitis C and in this case antiviral 
therapy should be given. 
In those with vasculitis, antiviral therapy should be 
combined with rituximab. High-dose steroids are effi-
cient against symptoms but should be avoid in the long 
term4. 
In patients with no detectable viral replication with 
recurrent symptoms or renal involvement, rituximab 
is the treatment of choice4. Total plasma exchange 
should be considered in rapidly progressive renal dis-
ease. Rituximab-containing regimens and bendamus-
tine can be used in all levels of renal dysfunction34. 
 CONCLUSION
MGRS are associated with a wide range of kidney dis-
eases resulting from the depositions of immunoglobulin or 
its components in the kidneys, or through the deregulation 
of the complement system. The likelihood of developing 
advanced chronic kidney disease is very high, although 
the mortality of patients with MGRS is lower than that 
of myeloma or other related gammopathies.
In MGRS, the clinical challenge begins with our ability 
to identify the underlying clone. So, an evaluation by 
a multidisciplinary team, that includes nephrologists 
and hematologists with expertise in this area, is highly 
recommended. Renal characteristics of the disease, 
risk of CKD progression, presence and severity of extra-
renal manifestations, safety profile of antineoplastic 
drugs in renal impairment should be all taken into 
account. After the correct diagnosis and stratification 
of the disease, the treatment should be instituted based 
on the International Kidney and Monoclonal Gammopa-
thy Working Group consensus4. 
Advances in the understanding of MGRS have made 
it possible to improve the prognosis of this disease. 
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